The intratumoral heterogeneity of EGFR expression in GBM may ultimately limit the clinical utility of therapies such as TKIs, antibody-based therapies, and RNA-based therapies, because it will not be possible to target every single neoplastic cell in the tumor population. This evidence concerns the gene EGFR and neoplasm.